发明名称 |
Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
摘要 |
Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof. |
申请公布号 |
US9433612(B2) |
申请公布日期 |
2016.09.06 |
申请号 |
US201514703660 |
申请日期 |
2015.05.04 |
申请人 |
CymaBay Therapeutics, Inc.;DiaTex, Inc. |
发明人 |
Roberts Brian K.;Saha Gopal Chandra;Lavan Brian Edward;McWherter Charles A. |
分类号 |
A61K31/192;A61K31/216;A61K31/426;A61K31/519;A61K45/06;A61K9/00;A61K9/10;A61K9/20;A61K9/48 |
主分类号 |
A61K31/192 |
代理机构 |
Hamilton, DeSanctis & Cha, LLP |
代理人 |
Nguyen Sam L.;Hamilton, DeSanctis & Cha, LLP |
主权项 |
1. An oral dosage composition comprising a therapeutically effective amount of:
(a) a first urate-lowering agent that is (−)-halofenate, or (−)-halofenic acid or a pharmaceutically acceptable salt thereof, substantially free from its (+)-enantiomer; and (b) a second urate-lowering agent that is febuxostat. |
地址 |
Newark CA US |